Drug development scientist with expertise in strategic design and analysis of clinical trials, with a specialty in liver disease

Amrik has broad expertise across the drug development continuum from Discovery through Phase 3 clinical trials, with therapeutic focus areas including MASH (metabolic dysfunction associated steatohepatitis) and advanced liver diseases, neurology (Parkinson’s, Alzheimer’s, ALS), infectious, and rare diseases. He started his career at Cleveland Clinic Foundation and was Head of Biometrics at both Shionogi and Intercept Pharma. Since 2018, he has been advisor to multiple biotech companies on drug development strategy, clinical endpoints and regulatory interactions with the FDA and EMA, particularly in the liver disease space